Other languages Seikagaku Corporation

Equities

4548

JP3414000004

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-05-31 am EDT			5-day change	1st Jan Change
787 ^JPY	+0.90%		+1.29%	+3.42%

Apr. 08	Ferring Pharmaceuticals Inc. Presents Pivotal Phase 3 Efficacy and Safety Data for Investigational Treatment, SI-6603, in Lumbar Disc Herniation at ASIPP 2024	CI
2023	Seikagaku Corporation Reports Earnings Results for the Full Year Ended March 31, 2023	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Seikagaku : Convocation Notice of the 78th Ordinary General Meeting of Shareholders	May. 22
Seikagaku : Financial Results for the Fiscal Year 2023	May. 16
Seikagaku : Announces the Biologics License Application for SI-6603 Has Been Accepted for Filing by the U.S. FDA	May. 13
Seikagaku : Consolidated Financial Results for the Fiscal Year Ended March 31, 2024	May. 13
Seikagaku : Consolidated Financial Results (Summary) for Fiscal 2023(Year Ended March 31, 2024)	May. 13
Ferring Presents Pivotal Phase 3 Efficacy and Safety Data for Investigational Treatment, SI-6603, in Lumbar Disc Herniation at ASIPP 2024	Apr. 09
Seikagaku : Announces an Academic Conference Presentation on SI-6603 by Licensee Ferring Pharmaceuticals Inc.	Apr. 08
Ferring Pharmaceuticals Inc. Presents Pivotal Phase 3 Efficacy and Safety Data for Investigational Treatment, SI-6603, in Lumbar Disc Herniation at ASIPP 2024	Apr. 08
Final dividend	Mar. 27	FA
Seikagaku : Financial Results for the Second Quarter of Fiscal Year 2023	Nov. 09
Ex-dividend day for interim dividend	23-09-27	FA
Seikagaku : Consolidated Financial Results (Summary) for the First Three Months of Fiscal 2023 (Three-Month Period Ended June 30, 2023)	23-08-04
Seikagaku : Financial Results for the First Quarter of Fiscal Year 2023	23-08-04
Ferring Announces Positive Topline Phase 3 Results for SI-6603, an Investigational Treatment for Lumbar Disc Herniation	23-05-29
Seikagaku : Announces the Topline Results from a Phase III Clinical Study (Additional Study) in the U.S. for SI-6603, a Treatment for Lumbar Disc Herniation	23-05-25
Seikagaku : Convocation Notice of the 77th Ordinary General Meeting of Shareholders	23-05-21
Seikagaku : Convocation Notice of the 77th Ordinary General Meeting of Shareholders	23-05-18
Seikagaku : Consolidated Financial Results (Summary) for Fiscal 2022(Year Ended March 31, 2023)	23-05-12
Seikagaku Corporation Reports Earnings Results for the Full Year Ended March 31, 2023	23-05-12
Seikagaku : Financial Results for the Fiscal Year 2022	23-05-11

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Seikagaku Corporation

Equities

4548

JP3414000004

Other languages

Filters